This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Mithra Pharmaceuticals Toekomstige groei
Future criteriumcontroles 1/6
Mithra Pharmaceuticals is forecast to grow earnings and revenue by 79% and 14.1% per annum respectively while EPS is expected to grow by 94.4% per annum.
Belangrijke informatie
79.0%
Groei van de winst
94.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 16.1% |
| Inkomstengroei | 14.1% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 26 Oct 2023 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2025 | 95 | 8 | 73 | 82 | 3 |
| 12/31/2024 | 59 | -29 | -21 | -12 | 3 |
| 12/31/2023 | 71 | -39 | -7 | 2 | 3 |
| 6/30/2023 | 63 | -79 | -28 | -9 | N/A |
| 3/31/2023 | 65 | -69 | -55 | -33 | N/A |
| 12/31/2022 | 67 | -60 | -82 | -57 | N/A |
| 9/30/2022 | 44 | -76 | -92 | -68 | N/A |
| 6/30/2022 | 22 | -93 | -102 | -78 | N/A |
| 3/31/2022 | 22 | -105 | -100 | -78 | N/A |
| 12/31/2021 | 23 | -117 | -98 | -77 | N/A |
| 9/30/2021 | 21 | -115 | -94 | -75 | N/A |
| 6/30/2021 | 19 | -113 | -91 | -73 | N/A |
| 3/31/2021 | 14 | -103 | -94 | -77 | N/A |
| 12/31/2020 | 9 | -92 | -96 | -80 | N/A |
| 9/30/2020 | 44 | -31 | -85 | -70 | N/A |
| 6/30/2020 | 79 | 29 | -73 | -59 | N/A |
| 3/31/2020 | 88 | 1 | -68 | -53 | N/A |
| 12/31/2019 | 97 | -27 | -62 | -47 | N/A |
| 9/30/2019 | 84 | -54 | -42 | -28 | N/A |
| 6/30/2019 | 71 | -82 | -21 | -5 | N/A |
| 3/31/2019 | 64 | -55 | -14 | -1 | N/A |
| 12/31/2018 | 58 | -28 | -7 | 4 | N/A |
| 9/30/2018 | 46 | -41 | -23 | -9 | N/A |
| 6/30/2018 | 33 | -53 | -40 | -25 | N/A |
| 3/31/2018 | 33 | -46 | -44 | -28 | N/A |
| 12/31/2017 | 32 | -38 | -47 | -31 | N/A |
| 9/30/2017 | 26 | -37 | -47 | -32 | N/A |
| 6/30/2017 | 20 | -36 | -46 | -32 | N/A |
| 3/31/2017 | 21 | -36 | N/A | -28 | N/A |
| 12/31/2016 | 22 | -35 | N/A | -23 | N/A |
| 9/30/2016 | 21 | -29 | N/A | -23 | N/A |
| 6/30/2016 | 20 | -23 | N/A | -22 | N/A |
| 3/31/2016 | 20 | -16 | N/A | -20 | N/A |
| 12/31/2015 | 20 | -10 | N/A | -18 | N/A |
| 9/30/2015 | 19 | -9 | N/A | -15 | N/A |
| 6/30/2015 | 18 | -8 | N/A | -12 | N/A |
| 3/31/2015 | 19 | -5 | N/A | -6 | N/A |
| 12/31/2014 | 19 | -3 | N/A | -1 | N/A |
| 12/31/2013 | 18 | -2 | N/A | 1 | N/A |
| 12/31/2012 | 15 | -1 | N/A | 1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: MITRAb is forecast to remain unprofitable over the next 3 years.
Winst versus markt: MITRAb is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: MITRAb is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: MITRAb's revenue (14.1% per year) is forecast to grow faster than the UK market (4% per year).
Hoge groei-inkomsten: MITRAb's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if MITRAb's Return on Equity is forecast to be high in 3 years time